Newsfeeds Archive - Spark Newswire

4 minute read

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study Of Allosteric BCR-ABL Inhibitor TERN-701 In Adult Healthy Volunteers And Highlights Potential For Competitive Differentiation

April 29, 4:31 PM

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor classPharmacokinetic data show no clinically significant difference in exposure

TERN

4 minute read

Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Avi Kapoor

February 9, 2:18 PM

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.

AFRM

3 minute read

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs

By Lisa Levin

December 5, 10:05 AM

As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

ALT

4 minute read

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

December 4, 2:10 PM

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20 per unit.

ALK

2 minute read

SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday

By Lisa Levin

December 4, 11:33 AM

U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday.

ALK

3 minute read

Terns Pharmaceuticals Announces First Participant Dosed In Phase 1 Clinical Trial Of TERN-601 Oral GLP-1 Receptor Agonist For Treatment Of Obesity

By Benzinga Newsdesk

November 2, 5:19 PM

Phase 1 trial underway for Terns' first oral GLP-1R agonist candidate for obesity, with 28-day proof of concept data anticipated in 2H24 Oral GLP-1R agonist offers potential for weight loss and improved convenience

TERN

2 minute read

Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday

By Lisa Levin

August 10, 7:53 AM

Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on Wednesday.

ARHS

4 minute read

Terns Achieves Primary Endpoint And All Secondary Endpoints In Phase 2a DUET Trial Of THR-β Agonist TERN-501 In NASH

By Happy Mohamed

August 8, 5:42 PM

TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction

TERN

2 minute read

Analyst Ratings

12 Analysts Have This to Say About Terns Pharma

By Benzinga Insights

July 26, 11:00 AM

Terns Pharma (NASDAQ:TERN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

TERN

2 minute read

Terns Pharmaceuticals Is “Attractively Priced” Despite Pressure From Eli Lilly’s Obesity Data, Analyst Says

By Vandana Singh

June 28, 2:53 PM

Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was p

LLY